Bayer’s 2.45B Dollar Eye Deal Targets Glaucoma and Diabetic Retinopathy
Bayer (BAYN.DE) is acquiring privately held Perfuse Therapeutics in a transaction worth up to 2.45 billion dollars to expand and modernize its ophthalmology pipeline.
The agreement gives Bayer full control of Perfuse’s lead asset PER‑001, a mid‑stage eye drug that fits squarely into Bayer’s strategy to move beyond its aging Eylea franchise in retinal disease.
Focus on PER‑001
PER‑001 is a Phase II endothelin receptor antagonist designed as a potential disease‑modifying treatment for glaucoma and diabetic retinopathy, two of the leading causes of vision loss worldwide.
Rather than only lowering eye pressure or treating swelling, PER‑001 targets ischemia and impaired blood flow in the eye, aiming to protect or improve visual function over time.
Key financial terms
Under the deal, Bayer will pay 300 million dollars upfront, with additional development, regulatory, and commercial milestones bringing the total potential value to as much as 2.45 billion dollars.
Bayer also secures global rights to PER‑001 and Perfuse’s underlying platform for ischemia‑driven eye diseases, positioning itself for long‑term return if the drug succeeds across multiple indications.
Why it matters for Bayer’s eye franchise
Bayer’s current flagship eye drug, Eylea, is facing biosimilar competition and pricing pressure, making new growth drivers in ophthalmology increasingly important.
By adding PER‑001, Bayer is doubling down on chronic, high‑need conditions like glaucoma and diabetic retinopathy, where a truly disease‑modifying therapy could command meaningful market share and support long‑term revenue.
